Good news!
"... Now, scientists at Scripps Research have shown the feasibility of a completely different approach to combating fentanyl deaths: a vaccine that teaches the immune system to rapidly neutralize the drug before it reaches the brain in the first place. The research ... suggests that their vaccine candidate could work against not only fentanyl itself, but most fentanyl-related “designer drugs”—altered versions of fentanyl made to boost its effects or evade detection. ...
When the team tested the resulting antibodies against different fentanyl designer drugs, the vaccine showed exactly the kind of pan specificity they had been looking for. The antibodies bound tightly to fentanyl and other dangerous variants—including carfentanil, China White, acetylfentanyl and furanylfentanyl. Yet they ignored clinically used opioids like morphine, oxycodone, remifentanil and alfentanil.
More importantly, when vaccinated mice were given fentanyl doses that would normally cause severe respiratory depression, the animals’ breathing remained nearly normal. Measurements of fentanyl concentration in the brain showed that the vaccine had reduced levels there by roughly 70% compared to mice that didn’t receive the vaccine. ..."
From the abstract:
"Synthetic opioids pose a chemically evolvable threat, in which extreme potency and rapid diversification allow fentanyl analogues to outpace structure-specific countermeasures. Immune strategies largely responded by copying the parent chemotype, implicitly treating small-molecule recognition as scaffold-dependent. Here, we examined an alternative hypothesis: adaptive immunity can recover fentanyl-class identity from transferable spatial and physicochemical information. Replacing the canonical piperidine of fentanyl with a 2-azaspiro[3.3]heptane, we created a chemically orthogonal immunogen with a radically altered three-dimensional arrangement.
Despite this, vaccination elicited high-titer cross-reactive antibodies, broad fentanyl-analogue binding, and protection matching a fentanyl-derived benchmark. Fentanyl antinociception shifted into the ∼1.1–2.1 mg kg–1 range, preserved ventilation during respiratory challenge, and reduced brain fentanyl from 61.9 ± 10.0 to 17.2 ± 0.7 nM.
These results reveal programmable antibody recognition, demonstrating that molecular class identity arises not from direct structural mimicry but through higher-order spatial and physicochemical relationships."
Redefining Drug Immune Recognition: A Radically Reconfigured Molecular Architecture Enables Broad Fentanyl-Class Protection (no public access)
Graphical abstract (?)
Fentanyl (yellow structure) and the antibody's binding pocket (green structure)—showing how the antibody recognizes the overall shape of the new molecule, rather than one particular scaffold.
No comments:
Post a Comment